-01.png)
Pasteurellosis kills 30%~40% of the world's goat and sheep populations, which leads to chronic infections and death.
STVac, 1st intranasal spray vaccine for small ruminant in the world to reduce mortality rate
STVac is the first Intranasal Spray Vaccine wholly developed by Malaysian scientists from Universiti Putra Malaysia (UPM) for protecting small ruminants such as goats and sheep against the respiratory diseases Mannheimia Haemolytica (also known as pneumonic pasteurellosis).
.png)
Effective to reduce
mortality rate
STVAC USES
RECOMBINANT
TECHNOLOGY
THE DISEASE
IS COMMON IN
GOATS AND SHEEP
POPULATIONS
WORLDWIDE,
LEADING TO
30% - 40% DEATHS
Learn more about STVac
Features
STVac is a recombinant inactivated bacterial vaccine produced in E. coli bacteria (as production host) that carries specific outer membrane protein (OMP 31) of M. haemolytica strain A7.
01
Vaccination via injection – stress to animals, high labour cost, time consuming.
04
98% effective to reduce mortality rate
07
Minimal animal handling - no stress to animal and handlers
02
Vaccine delivery via intranasal route which enhance both local and systemic immunities
05
Quick vaccine delivery
08
Pain free, no local reaction and preserve meat quality
03
Competitive price, ambient storage and extended product shelf life
06
Minimal training for handling vaccination
09
Zero withdrawal period for vaccine to clear from the animal's body
FUTURE PROJECT
Feed-based Vaccine for marine fishes and
Feed-based Enhancer for shrimps against Vibriosis.
Cost effective, safe, sustainable to replace antibiotics.
More effective than injectable vaccine.
About Us.
BIO-ANGLE VACS SDN. BHD., founded in 2013, BAV specializes in biotechnology for animal food, nutraceuticals and pharmaceuticals. BAV is the pioneer in the innovative animal health products which focusing on livestock and aquaculture health products. The state-of-the-art facility will be the first bacteria-based cGMP-accredited facility in Southeast Asia to manufacture animal health products
Facility
BAV adopts the requirements of Good Manufacturing Practice (GMP) in the production of our innovative animal health products. The GMP facility is the first bacterial based facility in Southeast Asia for veterinary products, and it is in the final stage of completion and certification.
Current capacity of GMP production equipped with 30 litre and 50 litre
fermenters would be able to produce 600,000 bottles per year
(100ml per bottles) equivalent to 60 million doses a year
for our first STVac Intranasal Spray vaccine product.
Secured sale and purchase contract = 100,000 bottles/Year
amounted to USD 42 Million
The GMP production cleanroom consists of main production areas which are Seed Room, Fermentation Room and Purification and Filling Room, while the support production areas are Solution Preparation Room and Washing Room.
The cleanroom is designed to comply with GMP guidelines for manufacturing of non-sterile intranasal animal vaccine in cleanroom grade D and C. The finished products which are filled and capped will be further sealed, labelled and packed in carton box in the Packaging Room, which is a Controlled Non-Classified (CNC) grade area.
60,000,000
Current Doses (per year) Production Capacity
WORLD'S FIRST
GMP
BIONEXUS
Intranasal Vaccine Production Facility for small ruminant
Hi tech International Standard GMP Facility
A Bionexus Status Company
Team
Professor Dr. Mohd Zamri Saad
Inventor & Technical Advisor
YBhg Tan Sri Dr Mohd Daud Bakar
Independent Non-Executive Chairman
Noor Shazreena Ishak
Chief Executive Officer
Seleman Arip
Founder & Advisor
